|
1
|
Irwin MS and Park JR: Neuroblastoma:
Paradigm for precision medicine. Pediatr Clin North Am. 62:225–256.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pinto NR, Applebaum MA, Volchenboum SL,
Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F,
Schleiermacher G, Park JR, et al: Advances in risk classification
and treatment strategies for neuroblastoma. J Clin Oncol.
33:3008–3017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peifer M, Hertwig F, Roels F, Dreidax D,
Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann
JM, et al: Telomerase activation by genomic rearrangements in
high-risk neuroblastoma. Nature. 526:700–704. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Franscini LC, Vazquez-Montes M, Buclin T,
Perera R, Dunand M, Grouzmann E and Beck-Popovic M: Pediatric
reference intervals for plasma free and total metanephrines
established with a parametric approach: Relevance to the diagnosis
of neuroblastoma. Pediatr Blood Cancer. 62:587–593. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shinagawa T, Kitamura T, Katanoda K,
Matsuda T, Ito Y and Sobue T: The incidence and mortality rates of
neuroblastoma cases before and after the cessation of the mass
screening program in Japan: A descriptive study. Int J Cancer.
140:618–625. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Armstrong GT, Chen Y, Yasui Y, Leisenring
W, Gibson TM, Mertens AC, Stovall M, Oeffinger KC, Bhatia S, Krull
KR, et al: Reduction in late mortality among 5-Year survivors of
childhood cancer. N Engl J Med. 374:833–842. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang SY, Bolch WE, Lee C, Van Brocklin
HF, Pampaloni MH, Hawkins RA, Sznewajs A, DuBois SG, Matthay KK and
Seo Y: Patient-specific dosimetry using pretherapy
[124I]m-iodobenzylguanidine ([124I]mIBG)
dynamic PET/CT imaging before [131I]mIBG targeted
radionuclide therapy for neuroblastoma. Mol Imaging Biol.
17:284–294. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kong G, Hofman MS, Murray WK, Wilson S,
Wood P, Downie P, Super L, Hogg A, Eu P and Hicks RJ: Initial
experience with gallium-68 DOTA-octreotate PET/CT and peptide
receptor radionuclide therapy for pediatric patients with
refractory metastatic neuroblastoma. J Pediatr Hematol Oncol.
38:87–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Louis CU and Shohet JM: Neuroblastoma:
Molecular pathogenesis and therapy. Annu Rev Med. 66:49–63. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kushner BH, Ostrovnaya I, Cheung IY, Kuk
D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K and Cheung
N-KV: Lack of survival advantage with autologous stem-cell
transplantation in high-risk neuroblastoma consolidated by anti-GD2
immunotherapy and isotretinoin. Oncotarget. 7:4155–4166. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Oliveira MR, Schuck PF and Bosco SMD:
Tanshinone I induces mitochondrial protection through an
Nrf2-dependent mechanism in paraquat-treated human neuroblastoma
SH-SY5Y cells. Mol Neurobiol. 54:4597–4608. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Almeida VR, Vieira IA, Buendia M, Brunetto
AT, Gregianin LJ, Brunetto AL, Klamt F, de Farias CB, Abujamra AL,
Lopez PLDC, et al: Combined treatments with a retinoid receptor
agonist and epigenetic modulators in human neuroblastoma cells. Mol
Neurobiol. 54:7610–7619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Radogna F, Cerella C, Gaigneaux A,
Christov C, Dicato M and Diederich M: Cell type-dependent ROS and
mitophagy response leads to apoptosis or necroptosis in
neuroblastoma. Oncogene. 35:3839–3853. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krytska K, Ryles HT, Sano R, Raman P,
Infarinato NR, Hansel TD, Makena MR, Song MM, Reynolds CP and Mossé
YP: Crizotinib synergizes with chemotherapy in preclinical models
of neuroblastoma. Clin Cancer Res. 22:948–960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Esposito MR, Aveic S, Seydel A and Tonini
GP: Neuroblastoma treatment in the post-genomic era. J Biomed Sci.
24:142017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Young K, Alusi G and Korbonits M: Novel
targeted treatment combinations for malignant neuroendocrine tumour
olfactory neuroblastoma. Endoc Abstr. 38:1532015.
|
|
17
|
Lattanzio F, Carboni L, Carretta D,
Candeletti S and Romualdi P: Treatment with the neurotoxic Aβ
(25–35) peptide modulates the expression of neuroprotective factors
Pin1, Sirtuin 1, and brain-derived neurotrophic factor in SH-SY5Y
human neuroblastoma cells. Exp Toxicol Pathol. 68:271–276. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
George SL, Falzone N, Chittenden S, Kirk
SJ, Lancaster D, Vaidya SJ, Mandeville H, Saran F, Pearson AD, Du
Y, et al: Individualized 131I-mIBG therapy in the
management of refractory and relapsed neuroblastoma. Nucl Med
Commun. 37:466–472. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bagatell R and Cohn SL: Genetic
discoveries and treatment advances in neuroblastoma. Curr Opin
Pediatr. 28:19–25. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Soriano A, París-Coderch L, Jubierre L,
Martínez A, Zhou X, Piskareva O, Bray I, Vidal I, Almazán-Moga A,
Molist C, et al: MicroRNA-497 impairs the growth of chemoresistant
neuroblastoma cells by targeting cell cycle, survival and vascular
permeability genes. Oncotarget. 7:9271–9287. 2016. View Article : Google Scholar : PubMed/NCBI
|
